Comparative, open, randomized trial of the efficacy and tolerance of slow-release 5-ASA suppositories once daily versus conventional 5-ASA suppositories twice daily in the treatment of active cryptogenic proctitis

被引:16
|
作者
Marteau, P
Florent, C
机构
[1] Hop Laennec, Serv Gastroenterol, Dept Gastroenterol, AP HP, F-75007 Paris, France
[2] Hop St Antoine, Dept Gastroenterol, AP HP, F-75571 Paris, France
来源
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2000年 / 95卷 / 01期
关键词
D O I
10.1111/j.1572-0241.2000.01679.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVE: The efficacy and tolerance of slow-release 5-ASA suppositories (Pentasa 1 g/day) were compared with those of conventional 5-ASA suppositories (Rowasa 0.5 g b.i.d.). METHODS: Two hundred and fifty-one (251) patients presenting with an exacerbation of cryptogenic proctitis were randomized. Clinical activity and rectal lesions were measured at days 1 and 14 land at day 21 for patients not in remission at day 14), and each patient had to fill out a daily diary card (checklist). RESULTS: Results are given for slow-release and classical suppositories, respectively. The reduction in symptoms and lesions was identical in both groups. Treatment was continued until day 21 in 36% versus 33% of the patients, and minor or moderate side effects occurred in 5.6% versus 6.3% (NS). The tolerance of the suppositories was rated as satisfactory every day by 77% versus 54% (p = 0.001), and early suppository expulsion occurred in 0.5% versus 3.3% (p = 0.001). CONCLUSIONS: The treatments were equally effective and both were well tolerated. However, the advantages of the slow-release suppositories were that patients exhibited greater tolerance and early expulsion was less frequent.
引用
收藏
页码:166 / 170
页数:5
相关论文
共 25 条
  • [1] A randomized trial comparing the efficacy tolerance of classical and slow release 5-ASA suppositories to treat acute attacks of ulcerative proctitis.
    Florent, C
    Marteau, P
    GASTROENTEROLOGY, 1998, 114 (04) : A977 - A977
  • [2] A CONTROLLED TRIAL ON THE EFFICACY AND COMPLIANCE OF 5-ASA ENEMAS VS 5-ASA SUPPOSITORIES IN DISTAL ULCERATIVE SIGMOIDITIS
    CAMPIERI, M
    LANFRANCHI, GA
    BRIGNOLA, C
    BAZZOCCHI, G
    GIONCHETTI, P
    MINGUZZI, MR
    BELLUZZI, A
    BASSO, O
    GASTROENTEROLOGY, 1986, 90 (05) : 1364 - 1364
  • [3] OPEN STUDY OF 5-ASA SUPPOSITORIES IN ULCERATIVE PROCTITIS (UP) AND ULCERATIVE-COLITIS (UC)
    SIDOROV, JJ
    WILLIAMS, CN
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1986, 9 (03): : A60 - A60
  • [4] Extent of disease in mild to moderate ulcerative proctitis: Comparison of 2 mesalamine (5-ASA) suppositories in a randomized trial
    de Montigny, D
    Ptak, T
    Lamet, M
    Dallaire, C
    Shah, U
    Spenard, J
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S304 - S304
  • [5] DOUBLE-BLIND, PLACEBO-CONTROLLED EVALUATION OF 5-ASA SUPPOSITORIES IN ACTIVE DISTAL PROCTITIS AND MEASUREMENT OF EXTENT OF SPREAD USING TC-99M-LABELED 5-ASA SUPPOSITORIES
    WILLIAMS, CN
    HABER, G
    AQUINO, JA
    DIGESTIVE DISEASES AND SCIENCES, 1987, 32 (12) : S71 - S75
  • [6] Extent of disease in mild to moderate ulcerative proctitis: Comparison of 2 mesalamine (5-ASA) suppositories in a randomized trialt Ptak
    Lamet, M
    Dallaire, C
    Shah, U
    Spenard, J
    De Montigny, D
    GASTROENTEROLOGY, 2005, 128 (04) : A331 - A331
  • [7] 5-ASA AND ACETYL-5-ASA IN PLASMA, URINE AND FECES FROM PATIENTS WITH INFLAMMATORY BOWEL-DISEASE DURING 3 G DAILY (TID 1 G) DOSING OF A SLOW RELEASE 5-ASA FORMULATION
    TJANDRAMAGA, TB
    VERBESSELT, R
    RUTGEERTS, P
    VANTRAPPEN, G
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (06) : 2383 - 2384
  • [8] A CONTROLLED RANDOMIZED TRIAL COMPARING 5-AMINOSALICYLIC ACID (5-ASA) 1G ONCE-DAILY VS 500MG BID IN TREATMENT OF ACTIVE PROCTITIS OR DISTAL PROCTOSIGMOIDITIS
    CAMPIERI, M
    GIONCHETTI, P
    BELLUZZI, A
    FERRETTI, M
    RIZZELLO, F
    BERRI, F
    PENNESTRI, D
    VANTURI, A
    BRIGNOLA, C
    MIGLIOLI, M
    BARBARA, L
    GASTROENTEROLOGY, 1995, 108 (04) : A790 - A790
  • [9] Once-daily, oral OPC-6535 in the treatment of active ulcerative colitis: Effect of concomitant 5-ASA use
    Hanauer, SB
    Keshavarzian, A
    Schollenberger, J
    Harris, MS
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S267 - S268
  • [10] Once-daily, oral tetomilast (OPC-6535) in a rat model of colitis: Comparative study on prevention and treatment versus 5-ASA
    Nagamoto, Hisashi
    Miyakoda, Goro
    Maeda, Takashi
    Sueyoshi, Shinobu
    Aoyama, Masashi
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S469 - S469